Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hesperidin and Diosmin for Paclitaxel-induced Neuropathy in Breast Cancer
NCT06811220Phase 3Not yet recruiting
- Sponsor
- Alexandria University
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
A Phase 3 trial of diosmin in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Alexandria University. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
diosmin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06811220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811220.